Estimating lifetime and 10-year risk of lung cancer. by Bruder, C. et al.
Contents lists available at ScienceDirect
Preventive Medicine Reports
journal homepage: www.elsevier.com/locate/pmedr
Estimating lifetime and 10-year risk of lung cancer☆
Christina Brudera, Jean-Luc Bulliarda, Simon Germanna, Isabelle Konzelmannb, Murielle Bochuda,
Magali Leyvraza, Arnaud Chioleroa,b,c,d,⁎
a Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland
bObservatoire Valaisan de la santé (OVS), Sion, Switzerland
c Institute of Primary Health Care (BIHAM), University of Bern, Switzerland
d Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Canada
A R T I C L E I N F O
Keywords:
Lung cancer
Risk communication
Lifetime risk
Public health indicator
Switzerland
A B S T R A C T
Lung cancer is the commonest cancer worldwide. Mortality and incidence rates are traditionally used to assess
cancer burden and as public health indicators. However, these metrics are diﬃcult to interpret at an individual
level. Providing the lifetime and 10-year risks of cancer could improve risk communication. Our aim was to
estimate current lifetime and 10-year risks of lung cancer by smoking status and changes in these risks between
1995 and 2013 in a Swiss population. We used all lung cancer cases recorded between 1995 and 2013 by two
population-based cancer registries in the contiguous cantons of Vaud and Valais, in Western Switzerland. We
estimated sex-speciﬁc lifetime risk and 10-year risk of lung cancer using the current probability method, ac-
counting for competing risk of death. Estimates were also provided by smoking status. Between 1995 and 2013,
9623 cases of lung cancer were recorded. During this period, the lifetime risk decreased in men from 7.1% to
6.7% and increased in women from 2.5% to 4.1%. In both sexes, the 10-year risk of lung cancer increased with
age until the age of 60–70 and decreased thereafter. Diﬀerence in the cumulative risk between current, former,
and never smokers were very large and reported in user-friendly charts to ease risk communication. These
lifetime and 10-year risk estimates could be used systematically as public health indicators. Regularly updating
risk estimations are necessary for conditions like lung cancer whose incidence has changed substantially.
1. Introduction
In 2012, lung cancer was the commonest diagnosed cancer in men
worldwide and the third most frequently diagnosed cancer in women,
after breast and colorectal cancer (Torre et al., 2015). In Switzerland,
between 2008 and 2012, it was the leading cause of cancer death in
men and the second cause of cancer death in women, after breast cancer
(Arndt et al., 2016). Because smoking is the major cause of lung cancer
(Janssen-Heijnen and Coebergh, 2001), trends in lung cancer incidence
are closely following trends in smoking habits in the population, with a
latency time of about 30 years (Oberli et al., 2016). In Switzerland,
smoking prevalence peaked in the 1950s in men and in the 1970s
among women (Oberli et al., 2016). Hence, lung cancer incidence
reached in men a peak in the 1980s and decreased thereafter (Janssen-
Heijnen and Coebergh, 2003; Levi et al., 1997). Among women, the
incidence has increased at least since the 1970s (Levi et al., 1997) and,
apparently, has not reached a peak yet (Rapiti et al., 2014).
Because cancers are feared diseases, an adequate risk
communication about the individual chance of developing cancer is
important (Schwartz et al., 1999; Gigerenzer et al., 2010; Kurz-Milcke
et al., 2008). To assess the burden of cancer, mortality and incidence
are frequently used. They are also standard public health indicators.
However, these epidemiological and population level metrics are not
simple to use for risk communication. Indeed, it might be diﬃcult for
lay persons to grasp one's own risk of having e.g. a lung cancer through
age-standardized or crude rates of incidence or mortality (Sasieni and
Adams, 1999). To improve health risk communication, we can estimate
the lifetime risk, which is the cumulative risk of being aﬀected by a
disease during the existence (Germann et al., 2016). Lifetime risk ap-
pears to be an informative and easily understood measure of the risk of
disease in individuals (Narayan et al., 2003). As many people are in-
terested in their own risk of disease in the near future (Woloshin et al.,
2008a), the cumulative 10-year risk, i.e. the probability, in percentage,
for a given individual of developing lung cancer in the next 10 years,
could be another interesting metric to help patients and health pro-
fessionals for health decision making (screening or change in health
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behavior) and to facilitate the discussions about cancer risk. Im-
portantly, these risks have to be regularly updated, following changing
incidence across time.
The lifetime risk of cancer has been estimated and is publicly
available in several countries, such as Canada or the United States. To
our knowledge, the 10-years cumulative risk is not systematically
computed by any country worldwide. Our goal was therefore to esti-
mate the sex-speciﬁc lifetime risk and 10-year risk of lung cancer in a
Swiss population, by smoking status, and assess changes in these risks
between 1995 and 2013. Further, we provided sex-speciﬁc user-friendly
tables and graphical tools for risk communication about lung cancer.
2. Material and methods
2.1. Study design
We conducted a population-based temporal trend study of the risk
of lung cancer in two regions of Western Switzerland (cantons of Vaud
and Valais) between 1995 and 2013. The total number of inhabitants in
the cantons of Vaud and Valais is 1,123,998 corresponding to 13% of
the total population of Switzerland.
2.2. Data source
In Switzerland, data on all new cancer cases are collected, docu-
mented and recorded by population-based regional cancer registries.
The National Institute for Cancer Epidemiology and Registration
(NICER) compiles and aggregates this data (www.nicer.org). Quality
control procedures are based on the guidelines from the European
Network of Cancer Registries (Working Group of the International
Association of Cancer R, 2005). Variables routinely harvested by Swiss
cancer registries include notably the birth date, sex, status at last
follow-up (alive, dead or left canton) and date of last follow-up of the
patient, as well as for each tumor its date of diagnosis (termed date of
incidence), localization, histological type, malignancy, stage TNM and
size.
We used data from the Vaud Cancer Registry (Registre Vaudois des
tumeurs; RVT) at the Institut Universitaire de Médecine Sociale et
Préventive (IUMSP; www.iumsp.ch) and the Valais Cancer Registry
(Registre Valaisan des tumeurs; RVsT) at the Observatoire Valaisan de
la Santé (OVS; www.ovs.ch). These registries collect data on all new
(incident) cases of cancer diagnosed in the cantons of Vaud and Valais,
since 1974 and 1989 respectively. Data on all cases of lung cancer re-
corded between 1995 and 2013 were used for this study. A recent
evaluation of the completeness of cancer case ascertainment in
Switzerland, including the Vaud and Valais Cancer Registries, indicated
a high completeness for most cancer types, including lung cancer (Lorez
et al., 2017). Annual mortality records were provided by the Federal
Statistical Oﬃce. Death rates of lung cancer were extracted from these
records. Information on smoking prevalence were obtained through
Suchmonitoring Schweiz (www.suchtmonitoring.ch).
2.3. Statistical analyzes
We analyzed trend data across 4 time periods, i.e., 1995–1998,
1999–2003, 2004–2008, and 2009–2013. Annual lung cancer incidence
and mortality rates, stratiﬁed by sex, were computed. Rates were age-
standardized to the European standard population (Curtin and Klein,
1995).
The current probability method was used to estimate the lifetime
risk (Sasieni et al., 2011). This method allows the estimation of cu-
mulative risk of any condition throughout lifetime, using the population
current incidence and mortality at each age. It accounts for the risk of
being aﬀected for the ﬁrst time by the condition at each age, and for the
competitive risk of dying (and not reaching that age) (Germann et al.,
2016; Sasieni et al., 2011). With data containing only primary tumors,
the current probability method is considered as the “gold standard” to
estimate the lifetime risk of any conditions during a given span of life
(Sasieni et al., 2011). To use this method, we estimated the number of
ﬁrst cancer cases and the number of cancer-free individuals (by deﬁ-
nition, not recorded in cancer registries). We also estimated the rates of
cancer (incidence) and of all-cause mortality (Ahmad et al., 2015). We
assumed that, within each time period considered, the incidence and
mortality rates of lung cancer were constant over time for each 5-year
age group. For each year of life, we calculated the risk (in %) of lung
cancer. The cumulative lifetime risk (in %) was computed for men and
women and for each time-period by the sum of these risks over the
lifespan.
We created a 10-year lung cancer cumulative risk table and chart,
inspired by Woloshin et al. (Woloshin et al., 2008b). To estimate the 10-
year cumulative risk of lung cancer at age A, we computed the diﬀer-
ence between the cumulative risk until age A+10 years and the cu-
mulative risk until age A. For example, the cumulative 10-year risk
since the age of 40 years old (that is, between the age of 40 and 49) is
the diﬀerence between the cumulative risk of having a lung cancer at
age 50 minus the cumulative risk at age 40. The 10-year risk was es-
timated at age 20, 30, 40, 50, 60, 70, 80, and 90. Since the risk of lung
cancer diﬀers by sex, we built separate tables and charts for men and
women.
We estimated the lifetime and 10-year risks by smoking status in-
directly (Woloshin et al., 2008b; Becher et al., 2018). First, we used the
sex-, age- and time-period speciﬁc prevalence of smoking in Switzer-
land (Supplemental Table S1). Second, we used the relative risk (RR) of
lung cancer associated with current and former smoking compared to
never smoking, derived from a recent systematic review (Lee et al.,
2012) (i.e., RR= 6.57 for current smokers below 60 years of age, 9.62
for current smokers between 60 and 69, 9.07 for current smokers
70 years old or more, and 4.30 for former smokers of all ages). For each
year of life, we calculated the risk (in %) of lung cancer by smoking
status with the following formulas:
•
=
+ ×
+ ×
Risk risk /(Prevalence
Prevalence RR
Prevalence RR )
never smokers whole population never smokers
current smokers current smokers
former smokers former smokers
•
= ×Risk risk RRcurrent smokers never smokers current smokers
•
= ×Risk risk RRformer smokers never smokers former smokers
The cumulative lifetime and 10-year risks were computed for cur-
rent, former, and never smokers by the sum of these risks over speciﬁc
lifespans.
2.4. Ethics
Anonymous health related personal data with no possibility to
identify individuals and recorded by cancer registries for research ac-
tivities were used. There was no threat to patient conﬁdentiality.
According to the Swiss Human Research Act (Humanforschungsgesetz
HFG), no ethical approval was needed for such analyses.
3. Results
Between 1995 and 2013, 9623 lung cancer cases were diagnosed in
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Vaud (69% of cases) and Valais (31% of cases), of which 6317 occurred
in men (66% of cases) and 3306 in women (34%) (Table 1 & Supple-
mental Table S2). The standardized incidence rate of lung cancer de-
creased by 27% in men (from 73/100,000 to 53/100,000 inhabitants)
and increased by 41% in women (from 22/100,000 to 31/100,000 in-
habitants) (Table 1). There were 7152 deaths from lung cancer in Vaud
(70% of deaths) and Valais (30%) between 1995 and 2013. During the
same time period, the standardized mortality rate of lung cancer de-
creased in men by 28% and increased in women by 19% (Table 1).
Mortality rates from lung cancer appear however to have stabilized in
women from 1999 to 2003 onwards. Between 1995 and 2013, the
prevalence of smoking decreased in men more than in women.
Fig. 1 shows the cumulative risk (in absolute %) of lung cancer in
men and women across age, per time period, between 1995 and 2013.
The darker the colour, the more recent the time-period. Across all ages,
the cumulative risk decreased in men between 1995 and 1998 and
2009–2013 whereas it increased in women. Although the cumulative
risk remained higher among men than women, the sex diﬀerence in
cumulative risk decreased with time.
The lifetime risk decreased in men from 7.1% to 6.7% (with a
maximum of 7.3% in 1999–2003) while it increased regularly among
women from 2.5% to 4.1%, between 1995 and 1998 and 2009–2013,
respectively (see Supplemental Fig. S1). The diﬀerence in lifetime risk
between men and women decreased with time.
The cumulative risk and lifetime risk of lung cancer, by sex, ages,
and smoking status are reported in Figs. 2 and 3. The diﬀerence in
cumulative risk was very large between current, former and non-smo-
kers, in both sexes and across all time-periods.
The 10-year risk (in absolute %) of lung cancer, by age group and
time-period in men and women, between 1995 and 2013 are shown in
Supplemental Table S3. Using estimates for the time period 2009–2013,
a 10-year risk chart was designed to facilitate the representation of the
individual risk of developing lung cancer over the next 10 years in men
and women between 40 and 90 years of age, according to smoking
status (Fig. 4). In both sexes, the 10-year risk of lung cancer increased
with age from age 40 to 70 and decreased thereafter.
4. Discussion
Between 1995 and 2013, the lifetime risk of lung cancer in
Switzerland has slightly decreased in men from 7.1% to 6.7% while it
increased in women from 2.5% to 4.1%. The diﬀerence in lifetime risk
has consequently decreased between men and women with time. The
10-year cumulative risk of lung cancer has decreased in men at all ages,
excepted in men over 80 years of age in whom the risk increased.
Among women, the 10-year cumulative risk increased from age
50 years onwards. Diﬀerence in the cumulative risk between current,
former, and never smokers were very large and reported in user-
friendly charts to ease risk communication. Updating risk estimations
are necessary for adequate communication on conditions like lung
cancer whose incidence has changed substantially. Further, these life-
time and 10 years cumulative risk estimates could be used system-
atically as public health indicators.
To our knowledge, no previous study has estimated the lifetime risk
and 10-year cumulative risk of lung cancer in Switzerland. While sev-
eral studies have estimated the lifetime or period-speciﬁc risk of being
diagnosed with any cancer, lifetime risk of lung cancer has been rarely
estimated in other countries. In Scotland, between 2001 and 2005, a
study estimated the lung cancer lifetime risk to be 8.8% in men and
6.5% in women (Sasieni et al., 2011). In Canada, the lifetime risk of
developing lung cancer was 8.1% in men and 4.7% in women between
1996 and 2000 (Chen, 2013). These lifetime risks are close, albeit
slightly higher, than our estimations. However, such comparisons are of
limited relevancy since these estimates strongly depend on the history
of smoking behaviors in the compared populations.
Several strengths of our study deserve to be noted. First, it is based
on high quality population data from two cancer registries recording all
cases of cancers in patients living in a region of Western Switzerland. It
allows us estimating reliably the incidence and mortality rates, as well
as the cumulative risk of lung cancer. Second, we used the current
probability method described as the gold standard for estimating cu-
mulative and lifetime risk with data containing only the ﬁrst primary
cancer (Sasieni et al., 2011). This method requires complete informa-
tion on the number of deaths in the population, to account for mortality
competitive risk. Of note, this method could easily be applied for other
Table 1
Standardized (European population) incidence and mortality rates per 100,000 inhabitants of lung cancer, by sex, per period, between 1995 and 2013, Vaud and
Valais, Switzerland (Source: Vaud and Valais Cancer Registries) and prevalence of current, former, and never smokers between 1995 and 2013 in Switzerland
(Source: Suchtmonitoring Schweiz). N: number; Δ: absolute and relative (in %) diﬀerence in incidence and mortality rates between time-periods.
Sex 1995–1998 1999–2003 2004–2008 2009–2013 Δ 1995–1998 to 2009–2013
N cases Men 1299 1685 1677 1656
Women 481 770 937 1118
Incidence rate/100,000 Men 73 69 62 53 −20 (−27%)
Women 22 27 29 31 +9 (+41%)
N deaths Men 937 1305 1310 1254
Women 370 573 668 735
Mortality rate/100,000 Men 54 53 48 39 −15 (−28%)
Women 16 19 20 19 +3 (+19%)
Prevalence of current smokers Men 39.1% 36.0% 32.3% 32.4% −6.7%
Women 27.8% 25.5% 23.6% 24.2% −3.6%
Prevalence of former smokers Men 23.3% 23.9% 24.3% 24.6% +1.3%
Women 15.5% 16.2% 18.2% 18.6% +3.1%
Prevalence of never smokers Men 37.6% 40.2% 43.4% 43.0% +5.4%
Women 56.8% 58.4% 58.2% 57.3% +0.5%
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Fig. 1. Cumulative risk (in absolute %) of lung cancer incidence, by sex, across
ages, per time-period, between 1995 and 2013, in Vaud and Valais,
Switzerland. (Source: Vaud and Valais Cancer Registries). The darker the
colour, the more recent the time-period.
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cancers and to other countries. Third, we provide up-to-date user-
friendly 10-year risk charts that could be used for risk communication
about lung cancer.
Our study has also some limitations. It is restricted to two cantons of
Switzerland. Lung cancer standardized incidence rate decreased in
Switzerland between 1995 and 2013 from 66.9 to 50.1/100,000 and
increased in women during the same time period from 18.2 to 27.7/
100,000 (NICER: Foundation National Institute for Cancer
Epidemiology and Registration, 2013). These national incidence are
close to the incidence observed in Vaud and Valais, and our ﬁnding
could to some extend by valid for the whole country. However, our goal
was not to have accurate estimates for the whole country but to com-
pute (10-year and lifetime) cumulative risk of lung cancer and provide
user-friendly charts to ease risk communication. Another limitation is
that we had to estimate the risk by smoking status indirectly, using
relative risk of lung cancer (Woloshin et al., 2008b) and smoking pre-
valence from other sources. This approach might have under- or over-
estimate the diﬀerence in risk between current, former and never
smokers. While we developed user-friendly ﬁgures to ease the risk
communication, we did no test if they improve the risk understanding
among patients. Finally, the current probability method applies the sex-
and age-speciﬁc current cancer incidence and mortality rate as if they
were valid for a current cohort of ageing men or women; this would be
true only if these rates remained stable over time.
Information is central in health decision making for patients and
health professionals, as well as for policy makers (Woloshin and
Schwartz, 1999). To take some health decision (e.g., to be screened for
a cancer or to change health behaviors like smoking), patients and
physicians need to be informed about the risk of developing disease
over a deﬁned period of time. Providing understandable quantitative
information to patients and physicians can be challenging because in-
formation needs and understanding in numbers (health literacy) can
vary a lot between individuals (Woloshin and Schwartz, 1999). The
commonly used incidence and mortality rates are not adequate to grasp
the risk of developing a cancer over a deﬁned period of time. Lifetime
and 10-year risks provide absolute risk estimates and are more intuitive
metrics that could be more easily understood (Lloyd-Jones et al., 2006).
Furthermore, presenting a user-friendly 10-year risk chart eases the
person to realize the magnitude of health risk faced. Using that kind of
chart during medical visits could facilitate the information sharing
between doctors and patients, and help informed health decision
making. It would be also useful for public health policy makers and
health professionals to have health indicators based on these risk me-
trics. According to Woloshin et al. “useful messages about health risks
should address two questions: how big is my risk and how does this risk
compare with other risks” (Woloshin et al., 2008b). It would be
therefore useful to develop similar charts for other cancers and diseases
in order to put the risk in context and facilitate the representation of the
magnitude of one's individual risk.
Importantly, risk of diseases need to be frequently updated in order
to convey correct and reliable information to patients and doctors. For
most diseases, risk charts have indeed a local or regional value, de-
pending on the risk level in a given population and can be outdated, if
the risk of disease changes promptly across time (Agarwal et al., 2009).
When estimating lifetime risk of disease, it is also necessary to account
for changes in life expectancy and in the competing risks of death. It is
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Fig. 2. Cumulative risk (in %) of lung cancer, by smoking status (A: current smokers, B: former smokers, C: never smokers), by sex, age, and time-period, between
1995 and 2013, Vaud and Valais, Switzerland.
Source: Vaud and Valais Cancer Registries, Switzerland
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Fig. 3. Lifetime risk (in %) of lung cancer, by smoking status (dark blue/pink: current smoker, medium blue/pink: former smoker, light blue/pink: never smoker), by
sex and time-period, between 1995 and 2013, Vaud and Valais, Switzerland.
Source: Vaud and Valais Cancer Registries, Switzerland
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Fig. 4. This chart represents the 10-year risk (in absolute %) of lung cancer, by smoking status, 10-years age group, and sex, for the most recent period (2009–2013),
Vaud and Valais, Switzerland. Each dot corresponds to one individual.
Source: Vaud and Valais Cancer Registries
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therefore necessary to update these risk charts, especially for conditions
like lung cancer whose incidence has changed substantially following
population-level changes in smoking behaviors.
5. Conclusion
Because mortality and incidence rates - both traditionally used to
assess cancer burden at a population level - might be diﬃcult to in-
terpret at an individual level, we propose life-time and 10-year risks to
be estimated systematically for all major cancers and used as public
health indicators. Charts showing the huge diﬀerence in cumulative risk
in current, former and never smokers could be used to help current
smokers realize the beneﬁt to quit smoking.
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